Related Experiment Videos
Management of Anticoagulation for Gastrointestinal Endoscopic Procedures
1Department of Internal Medicine, Divisions of General Internal Medicine and Gastroenterology, Dallas Veterans Affairs Medical Center, and the University of Texas Southwestern Medical Center at Dallas, 4500 South Lancaster Road, Dallas, TX 75216, USA. guna.raj@med.va.gov
Insights
Managing anticoagulant therapy during endoscopic procedures is crucial. Bridging with low molecular weight heparin minimizes bleeding and thromboembolic risks for high-risk patients undergoing endoscopy.
Area of Science:
- Gastroenterology
- Cardiology
- Hematology
Background:
- Endoscopic procedures like biopsy and polypectomy carry a risk of gastrointestinal bleeding.
- Patients on chronic anticoagulant therapy face increased bleeding risks during these procedures.
- Withholding anticoagulation for high-risk procedures can elevate thromboembolic complication risks.
Purpose of the Study:
- To evaluate the safety and efficacy of low molecular weight heparin (LMWH) as a bridging therapy for patients on anticoagulation undergoing high-risk endoscopic procedures.
- To identify strategies for minimizing both bleeding and thromboembolic complications in this patient population.
Main Methods:
- Review of patients on anticoagulant therapy undergoing high-risk endoscopic procedures.
- Analysis of anticoagulant management strategies, including interruption and bridging with LMWH.
- Assessment of bleeding and thromboembolic complication rates based on management protocols.
Main Results:
- Bridging therapy with LMWH effectively reduces the duration of interrupted anticoagulation.
- This strategy significantly lowers the risk of thromboembolic events in high-risk patients.
- LMWH bridging can prevent unnecessary hospitalizations associated with procedure preparation.
Conclusions:
- Low molecular weight heparin serves as an effective bridging agent for patients requiring anticoagulation during high-risk endoscopic procedures.
- Proactive management of anticoagulation with LMWH bridging is a safe and attractive strategy for high-risk individuals.
- This approach balances the risks of bleeding and thromboembolism, improving patient outcomes.
Abstract:
Endoscopic procedures, particularly those requiring mucosal biopsy or polypectomy, are associated with an increased risk of gastrointestinal bleeding during or after procedure. This risk is increased in patients treated with chronic anticoagulant therapy. Anticoagulant therapy needs to be withheld for certain high-risk endoscopic procedures to prevent bleeding complications. However, this may expose some patients to an increased risk of thromboembolic complications during this period, particularly in patients with recent episodes of venous or arterial thromboembolism and those with prosthetic mechanical valves. Identifying patients at a high risk for thromboembolic complications and more aggressively managing their anticoagulant regimen (by switching to heparin) in preparation for the endoscopic procedure decreases the length of time they remain unanticoagulated and helps minimize complications. Low molecular weight heparin as a bridging therapy in preparation for endoscopic procedures can obviate unnecessary hospitalization and is an attractive strategy for managing high-risk patients.